Overview

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

Status:
Completed

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find the optimal dose of SM04690 that can be safely given by intra-articular injection into the target knee joint of subjects with moderate to severe osteoarthritis.

Phase:

Phase 1

Details

Lead Sponsor:

Biosplice Therapeutics, Inc.
Samumed LLC

Treatments:

Lorecivivint